Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.

ABSTRACT:

Background

It is hypothesised that cotargeting the androgen receptor (AR) and paracrine androgen biosynthesis with enzalutamide and abiraterone acetate in metastatic castration-resistant prostate cancer (mCRPC) will dissipate adaptive feedback loops observed with either agent alone.

Objective

To assess the safety, efficacy, androgen signalling/metabolome, and drug-drug interactions (DDIs) of enzalutamide with abiraterone acetate in progressive bone mCRPC (bmCRPC).

Design, setting, and participants

This open-label, single-centre interventional study was conducted in bmCRPC patients.

Intervention

Enzalutamide 160mg and abiraterone acetate 1000mg once daily; prednisone 5mg twice daily.

Outcome measurements and statistical analysis

Adverse events (AEs), pros

SUBMITTER: Efstathiou E 

PROVIDER: S-EPMC7204265 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature